REGN · Regeneron Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$955.47
+4.28 (+0.45%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$98.84B
Shares
103.45M
Volume · Nov 13
1.17M
Avg daily vol (3M)
792.82K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Regeneron Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Regeneron Pharmaceuticals, Inc. (REGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Regeneron Pharmaceuticals, Inc. (REGN) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-01
Regeneron Pharmaceuticals, Inc. (REGN) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Regeneron Pharmaceuticals, Inc. (REGN) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-30
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Confident tone
Core commercial momentum
Oncology pipeline and late-stage development
Business development and external innovation
Revenue
$5.12B
▲ 36.3% YoY Diluted EPS
$18.45
▲ 35.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-10-01
Regeneron Pharmaceuticals, Inc. (REGN) October 1, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Regeneron Pharmaceuticals, Inc. (REGN) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Regeneron Pharmaceuticals, Inc. (REGN) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call Transcript
Confident tone
Dupixent growth and Sanofi collaboration
EYLEA HD franchise dynamics
Libtayo oncology momentum
Revenue
$4.29B
▲ 16.7% YoY Diluted EPS
$12.23
▼ 4.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-12
Regeneron Pharmaceuticals, Inc. (REGN) June 12, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Regeneron Pharmaceuticals, Inc. (REGN) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Regeneron Pharmaceuticals, Inc. (REGN) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Confident tone
DUPIXENT commercial performance
EYLEA HD growth and manufacturing
Pipeline breadth and R&D productivity
Revenue
$3.61B
▲ 19% YoY Diluted EPS
$6.75
▼ 7.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-30
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Confident tone
Dupixent growth and indication expansion
Factor XI antibody anticoagulant program
Libtayo oncology momentum
Revenue
$3.88B*
▲ 2.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
Confident tone
Dupixent growth and label expansion
Pipeline progress and pivotal data
EYLEA HD performance and headwinds
Revenue
$3.75B
▲ 0.9% YoY Diluted EPS
$13.62
▲ 18% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Positive tone
Dupixent growth and label expansion
EYLEA legacy decline
Libtayo franchise expansion
Revenue
$3.68B
▲ 3.6% YoY Diluted EPS
$12.81
▲ 3.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
Balanced tone
Dupixent growth and COPD launch
EYLEA franchise performance
Pipeline progress and regulatory milestones
Revenue
$3.03B
▼ 3.7% YoY Diluted EPS
$7.27
▲ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript
Confident tone
EYLEA HD label expansion and competitive pressure
Dupixent franchise and growth
LAG-3/PD-1 combo in melanoma and lung
Revenue
$3.79B*
▲ 10.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
Confident tone
EYLEA HD commercial performance and durability
Dupixent growth and COPD launch
Pipeline catalysts and readouts
Revenue
$3.72B
▲ 10.6% YoY Diluted EPS
$11.54
▲ 29.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Call Transcript
Confident tone
EYLEA HD launch
DUPIXENT growth and COPD expansion
Linvoseltamab / BCMA regulatory delay
Revenue
$3.55B
▲ 12.3% YoY Diluted EPS
$12.41
▲ 46% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript
Confident tone
Dupixent COPD regulatory review
Severe allergy combination approach
EYLEA HD launch momentum
Revenue
$3.15B
▼ 0.5% YoY Diluted EPS
$6.27
▼ 12.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript
Confident tone
EYLEA HD Launch and Execution
Dupixent Growth and COPD Expansion
Oncology Pipeline and Launches
Revenue
$3.43B*
▲ 0.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-05
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript
Revenue
$3.36B
▲ 14.5% YoY Diluted EPS
$8.89
▼ 23.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2023 Earnings Call Transcript
Revenue
$3.16B
▲ 10.5% YoY Diluted EPS
$8.50
▲ 13.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-10
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2023 Earnings Call Transcript
Revenue
$3.16B
▲ 6.6% YoY Diluted EPS
$7.17
▼ 16.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-03
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript
Revenue
$3.41B*
▼ 31% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Call Transcript
Revenue
$2.94B
▼ 15% YoY Diluted EPS
$11.66
▼ 18.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2022 Earnings Call Transcript
Revenue
$2.86B
▼ 44.4% YoY Diluted EPS
$7.47
▼ 73.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2022 Earnings Call Transcript
Revenue
$2.97B
▲ 17.3% YoY Diluted EPS
$8.61
▼ 14.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-04
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2021 Earnings Call Transcript
Revenue
$4.95B*
▲ 104.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2021 Earnings Call Transcript
Revenue
$3.45B
▲ 50.5% YoY Diluted EPS
$14.33
▲ 93.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2021 Earnings Call Transcript
Revenue
$5.14B
▲ 163.2% YoY Diluted EPS
$27.97
▲ 267.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2021 Earnings Call Transcript
Revenue
$2.53B
▲ 38.3% YoY Diluted EPS
$10.09
▲ 85.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript
Revenue
$2.42B
▲ 30% YoY Diluted EPS
$10.24
▲ 47.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2020 Earnings Call Transcript
Revenue
$2.29B
▲ 31.6% YoY Diluted EPS
$7.39
▲ 26.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2020 Earnings Call Transcript
Revenue
$1.95B
▲ 23.7% YoY Diluted EPS
$7.61
▲ 353% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2020 Earnings Call Transcript
Revenue
$1.83B
▲ 33.2% YoY Diluted EPS
$5.43
▲ 36.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–36 of 36 webcasts
Key facts
CIK
872589
CUSIP
75886F107
13F (30d)
1142 filings
1071 filers
Visit website
Investor relations